加载中
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
前收盘价
US$1.00
+US$0.02 · +2.04%
盘中时间采用ET。市场数据可能有所延迟。
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
日内区间
当前US$1.00
52周区间
当前US$1.00
盘中时间采用ET。市场数据可能有所延迟。
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
日内区间
当前US$1.00
52周区间
当前US$1.00
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 50.96万 USD | 15.24万 USD | 96.98万 USD | 35.58万 USD |
| 销货成本 | — | 763 USD | 30.2万 USD | 28.64万 USD | 5086 USD |
| 毛利 | — | 50.88万 USD | −14.96万 USD | 68.34万 USD | 35.07万 USD |
| 研究与开发 | 12.11万 USD | 17.93万 USD | 106.29万 USD | 269.35万 USD | 100.38万 USD |
| 销售、一般及管理费用 | 703.02万 USD | 503.48万 USD | 555.42万 USD | 1310.43万 USD | 1105.29万 USD |
| 营业费用 | 715.13万 USD | 521.41万 USD | 661.71万 USD | 1579.78万 USD | 1205.67万 USD |
| 利息收入 | 16.71万 USD | 8.74万 USD | 18.55万 USD | 18.78万 USD | 4.32万 USD |
| 利息支出 | 41.59万 USD | 82.59万 USD | 131.37万 USD | 29.4万 USD | 22.72万 USD |
| 折旧和摊销 | 50.48万 USD | 20.09万 USD | 38.04万 USD | 2.38万 USD | 1.2万 USD |
| 营业利润 | −715.13万 USD | −470.52万 USD | −676.67万 USD | −1511.44万 USD | −1170.6万 USD |
| 净利润 | −790.86万 USD | −490.29万 USD | −778.81万 USD | −1642.32万 USD | −1283.88万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年7月25日 | 1:10 | — | — |
股票拆分 | 2019年5月8日 | 1:18 | — | — |
股票拆分 | 2016年4月11日 | 157:50 | — | — |
股票拆分 | 2015年8月13日 | 1:5,000 | — | — |
股票拆分 | 2011年2月18日 | 1:5 | — | — |
股票拆分 | 2007年6月19日 | 1,573:1,000 | — | — |
已生效 2023年7月25日
1:10
已生效 2019年5月8日
1:18
已生效 2016年4月11日
157:50
已生效 2015年8月13日
1:5,000
已生效 2011年2月18日
1:5
已生效 2007年6月19日
1,573:1,000
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
